This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Bevacizumab
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | <applet load="" size="480" color="" frame="true" spin="on" Scene =" | + | <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Bevacizumab, also known as Avastin"/> |
| - | ===Better Known as: | + | ===Better Known as: Avastin=== |
| - | * Marketed By: | + | * Marketed By: Genentech & Roche<br /> |
| - | * Major Indication: [[ | + | * Major Indication: Colorectal [[Cancer]]<br /> |
| - | * Drug Class: [[ | + | * Drug Class: [[VEGF]] Inhibitor - [[Monoclonal Antibody]] |
| - | * Date of FDA Approval (Patent Expiration): | + | * Date of FDA Approval (Patent Expiration): 2004 ( |
| - | * | + | * 2009 Sales: $4.8 Billion<ref>Irena Melnikova, Therapies for Alzheimer's disease, Nature Reviews Drug Discovery 6, 341-342 (May 2007)</ref> |
| - | * Importance: | + | * Importance: It is one of the best selling [[cancer]] treatments in history. Despite being effective against colorectal cancer, post-approval studies after accelerated approval revealed that Avastin was ineffective in treating breast cancer. Many question the $90,000/year bill to take Avastin when it extends life on average only 10 months. |
* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | * The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | ||
===Mechanism of Action=== | ===Mechanism of Action=== | ||
| - | |||
| - | Rivastigmine is an [[Acetylcholinesterase]] (AChE) inhibitor. It binds to the active site of <scene name='Rivastigmine/Acetylcholinesterase/1'>AChE</scene>, utilizing many of the same residues which bind and break down acetylcholine. By inhibiting AChE, the important neurotransmitter, [[acetylcholine]], is degraded at a slower rate, helping reverse the marked decrease in neuronal function evident in [[Alzheimer's Disease]] patients. Rivastigmine is rapidly metabolized into its principal components (carbamyl and NAP moieties) which are powerful Acetylcholine inhibitors. These components primarily <scene name='Rivastigmine/Bound/1'>primarily interact with residues</scene> GLy 117, Gly 118, Gly 119 Ala 201, Trp 233, Phe 290, Trp 84, Phe 330, His 440, & Phe 288 in tightly binding to the AChE binding site via pi stacking and hydrogen bond interactions. Rivastigmine outcompetes acetylcholine for the active site of AChE, inhibiting the esterase<ref>PMID:11888271</ref> | ||
===Pharmacokinetics=== | ===Pharmacokinetics=== | ||
{| class="wikitable" border="1" width="30%" style="text-align:center" | {| class="wikitable" border="1" width="30%" style="text-align:center" | ||
|- | |- | ||
| - | ! colspan="2" align="center"| VEGF Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] | + | ! colspan="2" align="center"| VEGF Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>PMID:17093010</ref> |
|- | |- | ||
! Parameter | ! Parameter | ||
| Line 25: | Line 23: | ||
|- | |- | ||
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml) | ! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml) | ||
| - | ! | + | ! 284000 |
|- | |- | ||
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%) | ! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%) | ||
| - | ! | + | ! 100 |
|- | |- | ||
| - | + | ! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (days) | |
| - | + | ! 20 | |
| - | + | ||
| - | ! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] ( | + | |
| - | ! | + | |
|- | |- | ||
| - | ! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] ( | + | ! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ug/ml/hr) |
| - | ! | + | ! 97488 |
|- | |- | ||
! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM) | ! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM) | ||
| - | ! | + | ! .9 |
|- | |- | ||
! [[Pharmaceutical_Drugs#Clearance_.28Cl.29|Clearance]] (L/h) | ! [[Pharmaceutical_Drugs#Clearance_.28Cl.29|Clearance]] (L/h) | ||
| - | ! . | + | ! .0096 |
|- | |- | ||
! Dosage (mg/kg) | ! Dosage (mg/kg) | ||
! 10 | ! 10 | ||
| - | |- | ||
| - | ! Metabolism | ||
| - | ! [[Bevacizumab]] | ||
|} | |} | ||
Revision as of 11:35, 6 December 2010
|
Better Known as: Avastin
- Marketed By: Genentech & Roche
- Major Indication: Colorectal Cancer
- Drug Class: VEGF Inhibitor - Monoclonal Antibody
- Date of FDA Approval (Patent Expiration): 2004 (
- 2009 Sales: $4.8 Billion[1]
- Importance: It is one of the best selling cancer treatments in history. Despite being effective against colorectal cancer, post-approval studies after accelerated approval revealed that Avastin was ineffective in treating breast cancer. Many question the $90,000/year bill to take Avastin when it extends life on average only 10 months.
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Mechanism of Action
Pharmacokinetics
| VEGF Inhibitor Pharmacokinetics[2] | |
|---|---|
| Parameter | Bevacizumab |
| Tmax (hr) | 5.17 |
| Cmax (ng/ml) | 284000 |
| Bioavailability (%) | 100 |
| T1/2 (days) | 20 |
| AUC (ug/ml/hr) | 97488 |
| IC50 (nM) | .9 |
| Clearance (L/h) | .0096 |
| Dosage (mg/kg) | 10 |
References
- ↑ Irena Melnikova, Therapies for Alzheimer's disease, Nature Reviews Drug Discovery 6, 341-342 (May 2007)
- ↑ Garnier-Viougeat N, Rixe O, Paintaud G, Ternant D, Degenne D, Mouawad R, Deray G, Izzedine H. Pharmacokinetics of bevacizumab in haemodialysis. Nephrol Dial Transplant. 2007 Mar;22(3):975. Epub 2006 Nov 8. PMID:17093010 doi:10.1093/ndt/gfl664
Proteopedia Page Contributors and Editors (what is this?)
David Canner, Michal Harel, Joel L. Sussman, Alexander Berchansky
